Finally, monitoring for potential pharmacological drug interactions (involving CYP450 enzyme system and others) and possible side effects was recommended in 9 and 6% of cases, respectively. In the ...

Following these pharmacological and technological advances ... in practice Once a diagnosis of AS has been established, it is up to the treating physician to measure the clinical outcomes ...

Four families of efficacy endpoints were tested in hierarchical sequences with a step-down approach ... up to week 16 and two (1.5%) patients up to week 48; both had history of uveitis. There were no ...

Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...

A four year-long research study has found that particles secreted by an intestinal worm may assist in treating inflammatory ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

The expert considers that biomarkers could greatly benefit the broader inflammatory bowel disease (IBD) field if they are easy to assess and help predict clinical response. While Teva/Sanofi’s ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

IBD tends not to be continually active, and people who have it may go for extended periods without experiencing a flare-up of the symptoms ... is exploring similar approaches in other chronic ...

ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had ...